Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 10,535 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Shoulder Pathology in Manual Wheelchair Users

NCT02600910
View directory record Official record
Conditions
Paraplegia, Spinal Cord Injuries, Shoulder Pain, Tendinopathy
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
68
States / cities
Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting No phase listed Observational

Fractional Flow Reserve and Instantaneous Free-wave Ratio Revascularization Strategies in Women

NCT04599192
View directory record Official record
Conditions
Coronary Disease, Percutaneous Coronary Intervention, Exercise Test, Myocardial Perfusion Imaging, Cardiac Catheterization
Interventions
No study intervention
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional

Group Preconception Care for Fertility Patients

NCT05924464
View directory record Official record
Conditions
Infertility
Interventions
Group Preconception Care
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Percussion Therapy on the Biomechanics of Pickleball Movement

NCT07005934
View directory record Official record
Conditions
Injury;Sports, Muscle Soreness
Interventions
Theragun Prime
Device
Lead sponsor
Point Loma Nazarene University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 4 Interventional

Effects of Ocrevus in Relapsing Multiple Sclerosis

NCT04387734
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ocrelizumab, Platform
Drug
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cerebellar TDCS for SRPCS Treatment

NCT04760899
View directory record Official record
Conditions
Post-Concussion Syndrome
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 30 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 2 Interventional Results available

PhII ICb With/Without Erbitux in MBC Pts

NCT00248287
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

NCT07129252
View directory record Official record
Conditions
SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Interventions
CRN09682
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Duarte, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional

Augmenting the On-Scene Medic (ATOM): A Randomized, Controlled, Multicenter Study to Assess the Effectiveness of Augmented Reality Software on Prehospital Pediatric Medication Administration Accuracy

NCT07504211
View directory record Official record
Conditions
Medication Errors, Pediatric Medication Error
Interventions
Augmented reality software for pediatric drug dosing
Other
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 1 Interventional

Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

NCT01961063
View directory record Official record
Conditions
AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma, HIV Infection
Interventions
busulfan, lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics

NCT05986916
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver
Interventions
Liverscope® exam, MR exam, FibroScan® exam (optional), Blood draw, Body measurements, Questionnaires
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

NCT05478304
View directory record Official record
Conditions
Ischemic Stroke, Systemic Embolism
Interventions
AtriClip LAA Exclusion System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6,573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
102
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting No phase listed Observational

Opiophobia in Adults With Advanced Cancer

NCT07093567
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 2 Interventional

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

NCT05947500
View directory record Official record
Conditions
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
50
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032
View directory record Official record
Conditions
High-risk Non-muscle Invasive Bladder Cancer
Interventions
Pembrolizumab, BCG
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
44
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional

3D Printed Models for Mandibular Fracture Repair

NCT05733221
View directory record Official record
Conditions
Mandible Fracture, Maxillofacial Trauma
Interventions
3D Printed Model
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional

Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes

NCT06829914
View directory record Official record
Conditions
Common Femoral Artery Stenosis, Calcification; Heart
Interventions
Shockwave Catheter, CFA Endarterectomy
Device · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting No phase listed Observational

T1D Pregnancy & Me

NCT06959316
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Pregnancy in Diabetics, Pregnancy, High-Risk, Insulin Dependent Diabetes
Interventions
Hybrid closed loop insulin delivery system
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 3 Interventional

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
47
States / cities
Daphne, Alabama • Anaheim, California • Clovis, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

NCT05490771
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Linvoseltamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 15, 2026, 3:22 AM EST
Active, not recruiting Not applicable Interventional

CREST: Capsular Repair During Hip Arthroscopy

NCT03372564
View directory record Official record
Conditions
Hip Arthroscopy
Interventions
Hip Capsule Repair
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
3
States / cities
Scottsdale, Arizona • Westmont, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 15, 2026, 3:22 AM EST